NCT00556374 · CITED IN SOURCE DOCUMENTS

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase: PHASE3
Status at capture: COMPLETED
Registry last update: 2023-07-27

The purpose of this study is to determine whether denosumab compared to placebo, will reduce the rate of first clinical fracture in women with non-metastatic breast cancer receiving (non-steroidal) aromatase inhibitor therapy.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Time to First Clinical Fracture

→

outcome · POSTED

Percent Change From Baseline in Total Lumbar Spine Bone Mineral Density (BMD) at Month 36 at Pre-selected Sites

→

outcome · POSTED

Percent Change From Baseline in Total Hip BMD at Month 36 at Pre-selected Sites

→

outcome · POSTED

Percent Change From Baseline in Femoral Neck BMD at Month 36 at Pre-selected Sites

→

outcome · POSTED

Number of Participants With New Vertebral Fractures

→

outcome · POSTED

Number of Participants With New or Worsening Vertebral Fractures

→

outcome · POSTED

Disease-free Survival (DFS)

→

outcome · POSTED

Bone Metastases-free Survival (BMFS)

→

outcome · POSTED

Overall Survival (OS)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria for Double Blinded Phase: * Histologically or cytologically confirmed adenocarcinoma of the breast; * Female subjects with non-metastatic disease who are estrogen receptor (ER) and/or progesterone receptor (PR) positive, and who have completed their treatment pathway; * Subjects who are currently on, or will initiate an approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting; * Postmenopausal woman, defined as a woman fulfilling any one of the following criteria: * Having undergone a bilateral oophorectomy; * Age ≥ 60 years; * Aged \< 60 years meeting the following requirements: * Follicle-stimulating hormone (FSH) and estradiol in the postmenopausal range; * A negative pregnancy test within 7 days prior to randomization. Subjects who have undergone a hysterectomy do not require a pregnancy test. * More criteria may apply. Exclusion Criteria for Double Blinded Phase: * Aromatase inhibitor therapy for more than 24 months; * Prior or concurrent treatment with Selective Estrogen Receptor Modulators (eg, tamoxifen); * Evidence of metastatic disease; * Current or prior intravenous (IV) bisphosphonate administration; * Oral bisphosphonate treatment greater than or equal to 3 years continuously OR greater than 3 months but less than 3 years unless there was a washout period of at least 1 year prior to randomization OR any use during the 3-month period prior to randomization; * Prior administration of denosumab; * Known liver or renal deficiency; * Recurrence of the primary malignancy (e.g., during the allowed interval of pretreatment with aromatase inhibitor); * Diagnosis of any second non-breast malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma of the cervix uteri; * Any kind of disorder that compromises the ability to give written informed consent and/or comply with study procedures. Inclusion Criteria to Receive Open-label Phase Denosumab: * Obtain signed and dated written informed consent prior to performing any study-specific procedure; * Subjects currently taking an approved non-steroidal AIT (eg, anastrazole) or who have completed or discontinued AIT within 12 months prior to participation in the OLP; * Randomized to placebo arm during the double-blind phase (as determined by unblinding procedures); Exclusion Criteria to Receive Open-label Phase Denosumab: * Current or prior IV bisphosphonate administration; * Subjects meeting the following criteria for oral bisphosphonate treatment: * Greater than or equal to 3 years continuously, * Greater than 3 months but less than 3 years unless subject has had a washout period of at least 1 year prior to participation in the OLP, * Any use during the 3-month period prior to participation in the OLP; * Prior or concurrent treatment with SERMs (eg, tamoxifen); * Subjects who ended treatment with investigational product (IP) prematurely in the double-blind phase; Treatment with commercial denosumab (Prolia or Xgeva) prior to participation in the OLP. Eligibility for ZA substudy Inclusion Criteria * Obtain signed and dated written informed consent prior to performing any substudy-specific procedure * Subjects that received OLP denosumab and completed OLP treatment * Last OLP denosumab administration no longer than 9 months ago Exclusion Criteria * Current or prior ZA administration. * Subjects who ended treatment with investigational product (IP) prematurely in the double-blind phase and OL phase * Known sensitivity or intolerance to any of the products to be administered during the substudy (eg, ZA, calcium or vitamin D) * Known history of any of the following conditions either by subject self report or chart review * Paget's disease (bone), Cushing's disease, hyperprolactinemia or other active metabolic bone disease * Known history of hypocalcemia * Major surgery, or significant traumatic injury occurring within 4 weeks prior to randomization * Parathyroid glands in neck surgically removed. * Any sections of intestine removed. * Known human immunodeficiency virus infection * Active infection with hepatitis B or hepatitis C virus * Known liver or renal disease as determined by the investigator and indicated by the following criteria: * Aspartate aminotransferase ≥ 2.5 x ULN * Alanine transaminase ≥ 2.5 x ULN * Serum creatinine ≥ 2 x ULN * Creatine clearance \< 35ml/min Subjects that are pregnant or breastfeeding * All subjects with reproductive potential must have a negative pregnancy test within 7 days before randomization * Subjects who are osteoporotic in baseline BMD
healthy Volunteers: false
maximum Age: 100 Years
minimum Age: 45 Years
sex: FEMALE
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
intervention Names
Biological: Denosumab
Drug: Non-steroidal aromatase inhibitor therapy
label
Denosumab
type
EXPERIMENTAL
description
Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
intervention Names
Drug: Placebo
Drug: Non-steroidal aromatase inhibitor therapy
label
Placebo
type
PLACEBO_COMPARATOR
description
Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive a single 5 mg intravenous dose of zoledronic acid 8 months after the last open-label dose of denosumab.
intervention Names
Drug: Zoledronic Acid
label
SubStudy: Zoledronic Acid
type
EXPERIMENTAL
description
Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive standard of care 8 months after the last open-label dose of denosumab.
intervention Names
Other: Standard of Care
label
Substudy: Standard of Care
type
OTHER

interventions

arm Group Labels
Placebo
name
Placebo
other Names
Administered as a subcutaneous injection
type
DRUG
arm Group Labels
Denosumab
description
Administered as a subcutaneous injection
name
Denosumab
other Names
Prolia®
type
BIOLOGICAL
arm Group Labels
Denosumab
Placebo
description
An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting
name
Non-steroidal aromatase inhibitor therapy
type
DRUG
arm Group Labels
SubStudy: Zoledronic Acid
description
5 mg zoledronic acid administered at a constant infusion rate
name
Zoledronic Acid
other Names
Reclast
Zometa
type
DRUG
arm Group Labels
Substudy: Standard of Care
description
Standard of care (SoC) as recommended by the treating physician, depending on individual factors such as bone density, lifestyle recommendations by the Investigator such as diet, physical activities and sun exposure, as well as local treatment standards.
name
Standard of Care
type
OTHER

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: QUADRUPLE
who Masked: PARTICIPANT
CARE_PROVIDER
INVESTIGATOR
OUTCOMES_ASSESSOR

primary Purpose

SUPPORTIVE_CARE

Enrollment

count: 3420
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
The time to first on-study clinical fracture was defined as the number of days from randomization to the date of the x-ray confirming the clinical fracture. A clinical fracture is any clinically evident fracture with associated symptoms and confirmed by x-ray. Participants who died or withdrew without experiencing a clinical fracture were censored at the date of last contact or study termination whichever was earlier.
measure
Time to First Clinical Fracture
time Frame
From randomization until the primary analysis cut-off date of 26 March 2014; maximum time on main study at the cut-off was 87 months

secondary Outcomes

description
Bone mineral density was assessed by dual x-ray absorptiometry.
measure
Percent Change From Baseline in Total Lumbar Spine Bone Mineral Density (BMD) at Month 36 at Pre-selected Sites
time Frame
Baseline and Month 36
description
Bone mineral density was assessed by dual x-ray absorptiometry.
measure
Percent Change From Baseline in Total Hip BMD at Month 36 at Pre-selected Sites
time Frame
Baseline and Month 36
description
Bone mineral density was assessed by dual x-ray absorptiometry.
measure
Percent Change From Baseline in Femoral Neck BMD at Month 36 at Pre-selected Sites
time Frame
Baseline and Month 36
description
Assessment of vertebral fractures was performed by an expert radiologist at the central imaging center using a semiquantitative grading scale: Grade 1, 20% to 25% reduction in vertebral height (anterior, middle, or posterior); Grade 2, 25% to 40% reduction in height; Grade 3, greater than 40% reduction in height. A new vertebral fracture was defined as a fracture in a previously undeformed vertebrae including new compression fractures, defined as those compression fractures having a decrease in total anterior or posterior height of at least 25% from baseline. New vertebral fractures includes morphometric vertebral fractures identified from on study x-rays and clinical vertebral fractures confirmed by x-rays.
measure
Number of Participants With New Vertebral Fractures
time Frame
36 months
description
Assessment of vertebral fractures was performed by an expert radiologist at the central imaging center using a semiquantitative grading scale: Grade 1, 20% to 25% reduction in vertebral height (anterior, middle, or posterior); Grade 2, 25% to 40% reduction in height; Grade 3, greater than 40% reduction in height. A new vertebral fracture was defined as a fracture in a previously undeformed vertebrae including new compression fractures, defined as those compression fractures having a decrease in total anterior or posterior height of at least 25% from baseline. New vertebral fractures includes morphometric vertebral fractures identified from on study x-rays and clinical vertebral fractures confirmed by x-rays. Worsening of pre-existing fractures was defined as an increase in fracture severity of at least 1 grade on the semiquantitative scale.
measure
Number of Participants With New or Worsening Vertebral Fractures
time Frame
36 months
description
DFS was defined as the time interval from the randomization date to the date of first evidence of local or distant metastases, contra-lateral breast cancer, secondary carcinoma, or death from any cause (whichever occurred first). Participants last known to be alive, who did not experience recurrence of disease, were censored at their last contact date or at the data cut-off date whichever came first.
measure
Disease-free Survival (DFS)
time Frame
From randomization until the DFS data cut-off date of 15 September 2015; maximum time on main study at the cut-off was 102 months
description
BMFS was defined as the time interval from randomization to first occurrence of bone metastasis or death from any cause, whichever comes first. Participants last known to be alive, who did not experience bone metastasis, were censored at their last assessment (i.e., bone scan) date or at the last contact date, whichever comes first.
measure
Bone Metastases-free Survival (BMFS)
time Frame
From randomization until end of main study, maximum time on main study was 152 months
description
OS was defined as the time from randomization to death from any cause.
measure
Overall Survival (OS)
time Frame
Randomization until end of main study, maximum duration of main study was 152 months

Full study description

brief Summary: The purpose of this study is to determine whether denosumab compared to placebo, will reduce the rate of first clinical fracture in women with non-metastatic breast cancer receiving (non-steroidal) aromatase inhibitor therapy.
detailed Description: Participants will remain on treatment until the required number of events (where an event is defined as first clinical fracture) is reached and all participants have had the opportunity to receive a minimum of at least 2 doses of study drug, whichever occurs later. The primary analysis data cut-off date (PADCD) is defined as the time at which the required number of events is reached and all participants have had the opportunity to receive at least 2 doses of study drug. When the PADCD is reached, all participants will discontinue study drug. Following the study PADCD, participants will be followed every 12 months starting from their last study visit until a maximum of 66 months after PADCD. After approval of Amendment 4, willing and eligible participants randomized to placebo during the double-blind phase may participate in an open-label phase (OLP) and receive denosumab 60 mg Q6M for up to 36 months (maximum of 7 doses). After approval of Amendment 6 in 2019 a zoledronic acid (ZA) substudy was added to the protocol. Willing and eligible participants who participated in the OLP of the study and completed open-label denosumab may opt in to this ZA substudy and either receive a single dose of ZA (Therapy Arm), or be managed according to the current standard of care for this patient population (Control Arm).

Source references

references

citation
Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31.
pmid
26040499
type
BACKGROUND
citation
Adams A, Jakob T, Huth A, Monsef I, Ernst M, Kopp M, Caro-Valenzuela J, Wockel A, Skoetz N. Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis. Cochrane Database Syst Rev. 2024 Jul 9;7(7):CD013451. doi: 10.1002/14651858.CD013451.pub2.
pmid
38979716
type
DERIVED
citation
Gnant M, Frantal S, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Artner-Matuschek S, Kainberger F, Ritter M, Rinnerthaler G, Sevelda P, Bergh J, Kacerovsky-Strobl S, Suppan C, Brunner C, Deutschmann C, Gampenrieder SP, Fohler H, Jakesz R, Fesl C, Singer C. Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer. NEJM Evid. 2022 Dec;1(12):EVIDoa2200162. doi: 10.1056/EVIDoa2200162. Epub 2022 Nov 18.
pmid
38319865
type
DERIVED
citation
Minichsdorfer C, Fuereder T, Leutner M, Singer CF, Kacerovsky-Strobl S, Egle D, Greil R, Balic M, Fitzal F, Pfeiler G, Frantal S, Bartsch R, Gnant M. Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18. ESMO Open. 2022 Apr;7(2):100426. doi: 10.1016/j.esmoop.2022.100426. Epub 2022 Mar 22.
pmid
35334418
type
DERIVED
citation
Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Jakesz R, Marth C, Sevelda P, Mlineritsch B, Exner R, Fesl C, Frantal S, Singer CF; Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):339-351. doi: 10.1016/S1470-2045(18)30862-3. Epub 2019 Feb 19.
pmid
30795951
type
DERIVED